Five-year adjusted probabilities of end points by donor groups in the PTCy cohort
| End points at 5 years . | MSD, % (95% CI) . | MUD, % (95% CI) . | Haplo, % (95% CI) . | MMUD, % (95% CI) . |
|---|---|---|---|---|
| OS | 44 (38-49) | 52 (48-56) | 45 (41-48) | 46 (39-52) |
| DFS | 38 (33-43) | 45 (42-49) | 38 (35-41) | 43 (37-48) |
| NRM | 22 (17-28) | 19 (15-22) | 30 (26-34) | 23 (18-27) |
| Relapse | 48 (43-54) | 42 (37-46) | 41 (37-44) | 41 (34-48) |
| Acute grade 2-4 GVHD | 25 (22-28) | 27 (25-29) | 29 (26-31) | 26 (22-29) |
| Acute grade 3-4 GVHD | 9 (7-12) | 6 (5-8) | 7 (6-9) | 7 (4-9) |
| Chronic GVHD | 23 (20-27) | 22 (20-24) | 25 (22-27) | 26 (22-31) |
| End points at 5 years . | MSD, % (95% CI) . | MUD, % (95% CI) . | Haplo, % (95% CI) . | MMUD, % (95% CI) . |
|---|---|---|---|---|
| OS | 44 (38-49) | 52 (48-56) | 45 (41-48) | 46 (39-52) |
| DFS | 38 (33-43) | 45 (42-49) | 38 (35-41) | 43 (37-48) |
| NRM | 22 (17-28) | 19 (15-22) | 30 (26-34) | 23 (18-27) |
| Relapse | 48 (43-54) | 42 (37-46) | 41 (37-44) | 41 (34-48) |
| Acute grade 2-4 GVHD | 25 (22-28) | 27 (25-29) | 29 (26-31) | 26 (22-29) |
| Acute grade 3-4 GVHD | 9 (7-12) | 6 (5-8) | 7 (6-9) | 7 (4-9) |
| Chronic GVHD | 23 (20-27) | 22 (20-24) | 25 (22-27) | 26 (22-31) |